| Range: | 5.26-75.2 | Vol Avg: | 1349045 | Last Div: | 0 | Changes: | 0.59 |
| Beta: | 1.1 | Cap: | 0.41B | Currency: | USD | Exchange: | NYSE |
| Sector: | Healthcare | IPO: | Mon Apr 19 2021 | Empoloyees: | 1218 | ||
| CUSIP: | 37611X100 | CIK: | 0001830214 | ISIN: | US37611X1000 | Country: | US |
| CEO: | Dr. Jason Kelly Ph.D. | Website: | https://www.ginkgobioworks.com | ||||
DNA 7.17 Stock Price Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow